Medibio Ltd
ASX:MEB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (38.4), the stock would be worth AU$-0.02 (202% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -37.8 | AU$0.02 |
0%
|
| Industry Average | 38.4 | AU$-0.02 |
-202%
|
| Country Average | 18.1 | AU$-0.01 |
-148%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Medibio Ltd
ASX:MEB
|
122m AUD | -37.8 | -39.1 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 88.6 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 36.2 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
28.1B USD | 20.3 | 30.9 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.2B AUD | 119.4 | 60.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 23.5 | 20.5 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.2B SEK | 79.2 | 91.5 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.6B USD | 15.1 | 19.3 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4B USD | 8.6 | 35 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
283.9B INR | -201.6 | 42.8 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.1B CNY | 80 | -62.1 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 12.5 |
| Median | 18.1 |
| 70th Percentile | 35.6 |
| Max | 5 049.1 |
Other Multiples
Medibio Ltd
Glance View
Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. The firm offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company offers a software called MEBsleep, a medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. The Company’s subsidiaries include Bioprospect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Medibio Limited USA, Invatec Health Pty Ltd and Annapanna Pty Ltd.
